Synonyms: (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl) cyclohexanecarboxamide dihydrochloride; (R)-(+)-trans-4-(1-Aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide Dihydrochloride
Health Benefits of Y-27632 Dihydrochloride
Y-27632 has been widely used as a research tool to study the role of ROCK in cellular and physiological processes. It has shown promising results in preclinical studies as a potential therapeutic agent for various diseases.
Cardiovascular diseases: Y-27632 has been shown to improve cardiac function and reduce the effects of myocardial infarction in animal models.
Neurodegenerative diseases: Y-27632 can reduce neuroinflammation and neuronal death in models of Alzheimer's and Parkinson's diseases.
Cancer: Y-27632 can inhibit tumor growth and metastasis in certain cancer cell lines.
Respiratory diseases: Y-27632 has been shown to improve lung function and reduce inflammation in models of asthma and chronic obstructive pulmonary disease (COPD).
Stem cell research: Y-27632 has been used to enhance the survival and proliferation of stem cells in vitro and in vivo.
Potential Effects of Y-27632 Dihydrochloride
Inhibition of ROCK: Y-27632 selectively inhibits ROCK, a key regulator of cytoskeletal organization and cell adhesion, resulting in changes in cell shape and motility.
Improvement of tissue repair: Y-27632 can enhance tissue repair and regeneration by promoting stem cell proliferation and differentiation, as well as reducing inflammation.
Cardiovascular protection: Y-27632 may protect against oxidative stress and improve cardiovascular function by reducing vasoconstriction and promoting vasodilation.
Neuronal protection: Y-27632 can protect neurons from apoptosis, oxidative stress, and inflammation by inhibiting ROCK activation.
Product Mechanism
Y-27632 dihydrochloride selectively inhibits ROCK, a serine/threonine kinase that regulates cytoskeletal organization, cell adhesion, migration, and proliferation. ROCK is activated by RhoA, a small GTPase that promotes actin polymerization and stress fiber formation. By inhibiting ROCK, Y-27632 prevents actin polymerization, leading to changes in cell shape and motility. The inhibition of ROCK also reduces matrix metalloproteinase (MMP) expression, which plays a critical role in extracellular matrix (ECM) remodeling and cellular invasion.
Safety
Y-27632 dihydrochloride is generally considered safe at therapeutic doses. However, it may cause some side effects, as discussed below. It is recommended to follow the dosing guidelines and safety precautions when using this product.
Side Effects
Hypotension: Y-27632 can cause a drop in blood pressure, leading to hypotension in some patients.
Gastrointestinal disorders: Y-27632 can cause nausea, vomiting, and diarrhea in some patients.
Renal impairment: Y-27632 can cause renal impairment in some patients, especially those with preexisting renal dysfunction.
Hepatotoxicity: Y-27632 can cause hepatotoxicity in some patients, leading to liver damage and dysfunction.
Dosing Information
Y-27632 dihydrochloride is usually administered at doses ranging from 1-10 μM in vitro and 10-30 mg/kg in vivo. The optimal dose may vary depending on the specific application and experimental conditions. It is recommended to follow the dosing guidelines provided by the supplier and to consult with a healthcare professional before using this product.
Conclusion
Y-27632 dihydrochloride is a selective inhibitor of ROCK that has gained substantial attention in recent years due to its potential therapeutic applications in various diseases. It has shown promising results in preclinical studies as a potential therapeutic agent in cardiovascular, neurodegenerative, and respiratory diseases. Y-27632 has also been used as a research tool to study the role of ROCK in cellular and physiological processes. While Y-27632 is generally considered safe, it may cause some side effects at therapeutic doses, and caution should be exercised when using this product.
